Literature DB >> 23373991

New insights into the role of NF1 in cancer.

L Sabova1, M Kretova, K Luciakova.   

Abstract

NF1 proteins are a family of transcription factors that act either as repressors or as activators. Functional studies indicate that NF1 participate in signaling pathways that regulate cell viability, proliferation and differentiation. Participation in regulation of genes important for tumor progression and metastasizing suggests a potential value of NF1 as a prognostic factor for certain types of cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23373991     DOI: 10.4149/neo_2013_031

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.

Authors:  A Alholle; A T Brini; J Bauer; S Gharanei; S Niada; A Slater; D Gentle; E R Maher; L Jeys; R Grimer; V P Sumathi; F Latif
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 2.  Nuclear Factor I/B: A Master Regulator of Cell Differentiation with Paradoxical Roles in Cancer.

Authors:  Daiana D Becker-Santos; Kim M Lonergan; Richard M Gronostajski; Wan L Lam
Journal:  EBioMedicine       Date:  2017-05-27       Impact factor: 8.143

3.  Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy.

Authors:  Renata Veselska; Marta Jezova; Michal Kyr; Pavel Mazanek; Petr Chlapek; Viera Dobrotkova; Jaroslav Sterba
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

4.  Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.

Authors:  Liye Wang; Qinglian Zhai; Qianyi Lu; Kaping Lee; Qiufan Zheng; Ruoxi Hong; Shusen Wang
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 5.  Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.

Authors:  Ruoning Yang; Yueyi Li; Hang Wang; Taolin Qin; Xiaomeng Yin; Xuelei Ma
Journal:  Mol Biomed       Date:  2022-03-04

Review 6.  Therapeutic landscape in mutational triple negative breast cancer.

Authors:  Yaqin Shi; Juan Jin; Wenfei Ji; Xiaoxiang Guan
Journal:  Mol Cancer       Date:  2018-07-14       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.